FAIRFAX, Va., August 26, 2026 /PRNewswire/ — Virginia Cancer Specialists, ranked #1 practice in Virginia for cancer care and across all medical specialties by Castle Connolly, is pleased to welcome Kai-Li Liang, MD. Dr. Liang is a board certified medical oncologist and clinical investigator whose expertise will further strengthen one of the region’s most advanced and comprehensive cancer research programs.
Dr. Liang completed fellowship training in Medical Oncology at Johns Hopkins University School of Medicine after serving as Chief Resident and completing his residency in Internal Medicine at Johns Hopkins Bayview Medical Center. Dr. Liang earned his medical degree from Stony Brook University School of Medicine and his bachelor’s degree in microbiology from the University of Maryland.
Dr. Liang joins Virginia Cancer Specialists at a pivotal time of growth for the practice’s research and clinical trials program. With the largest community-based oncology clinical trials portfolio in the Mid-Atlantic region, Virginia Cancer Specialists continues to expand patient access to groundbreaking therapies. Dr. Liang’s arrival enhances Virginia Cancer Specialists’ ability to bring next-generation therapies to patients closer to home through participation in leading national and international clinical trials.
“Virginia Cancer Specialists has long been recognized as a leader in community-based cancer research, and we are thrilled to welcome Dr. Liang to our team,” said Alex Spira MD, PhD, FACP, FASCO, Co-Director of the Virginia Cancer Specialists Research Institute and a nationally recognized clinical investigator. “His passion for advancing cancer treatment through clinical research aligns perfectly with our mission to bring the most innovative therapies directly to patients. As we continue expanding our research platform, Dr. Liang will play an important role in helping us accelerate access to the latest treatment opportunities throughout the region.”
Virginia Cancer Specialists has been at the forefront of research advancement for decades, providing patients with access to clinical trials that may not otherwise be available in the community setting. The practice collaborates with leading pharmaceutical companies, cooperative research groups, and academic institutions to evaluate emerging therapies across a broad spectrum of cancer types.
“I’m excited to be joining the team at Virginia Cancer Specialists and to help bring next generation cancer therapies to patients,” said Dr. Liang. “Early-phase clinical research is advancing how we treat cancer and I look forward to providing meaningful new options for patients.”
In addition to expanding the research program, Dr. Liang will provide comprehensive cancer care while contributing to the development and execution of clinical studies designed to improve outcomes and quality of life for patients facing cancer.
With 10 locations across Northern Virginia, Virginia Cancer Specialists remains committed to delivering world-class cancer care through a combination of compassionate treatment, multidisciplinary expertise, and a robust research infrastructure that continues to shape the future of oncology.
